Enanta to present Phase 2 trial data for RSV drug candidate zelicapavir at IDWeek 2026
ENTA•Enanta flagged Phase 2 results for zelicapavir, reporting faster symptom resolution, fewer hospitalizations and lower viral burden than placebo in high-risk adults; the data are scheduled for presentation on Oct. 22, 2026.
1. Trial results
Enanta Pharmaceuticals flagged new Phase 2 results for RSV drug candidate zelicapavir. The trial data indicate faster symptom resolution, fewer hospitalizations and lower viral burden versus placebo in high-risk adults; the presentation is set for Oct. 22, 2026.
